Real-World Epidemiology, Clinical Characteristics and Outcomes of Women with Germline BRCA Mutation and Early Breast Cancer in China
Characteristics, treatment patterns and outcomes were distinct among patients in China with gBRCAm eBC. Our findings support wider implementation of gBRCA testing for all patients in China with HER2-negative eBC, beyond those with triple-negative tumour subtype and/or family history of cancer, to identify more patients who may benefit from targeted therapy. Infographic available for this article.
Authors
- Zhen Hu (ORCID: https://orcid.org/0000-0001-8227-5056)
- Mengyu Xie (ORCID: https://orcid.org/0000-0002-4661-9891)
- Meng Ru (ORCID: https://orcid.org/0000-0002-1439-6451)
- Luis C. Berrocal-Almanza (ORCID: https://orcid.org/0000-0003-1634-9971)
- Tingting Su (ORCID: https://orcid.org/0000-0002-1053-8352)
- Xiaoqing Xu (ORCID: https://orcid.org/0000-0002-7918-5129)
- Zhimin Shao
- Tianyu Zhao (ORCID: https://orcid.org/0000-0002-6852-0040)
- Qianqian Yu (ORCID: https://orcid.org/0000-0002-5582-7975)
- Liqin Chen (ORCID: https://orcid.org/0000-0002-5371-7158)
- Miao Feng (ORCID: https://orcid.org/0000-0001-6833-8268)
- Miguel Miranda
Institutions
- AstraZeneca (United Kingdom) (GB)
- Shanghai Medical College of Fudan University (CN)
- Fudan University (CN)
- Fudan University Shanghai Cancer Center (CN)
- SGIDI Engineering Consulting (China) (CN)
- AstraZeneca (United States) (US)
Publication Details
- Journal
- Oncology and Therapy
- Published
- 2025-10-26
- DOI
- https://doi.org/10.1007/s40487-025-00384-w
- Primary Topic
- BRCA gene mutations in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00